NEW YORK (GenomeWeb) – German molecular diagnostics firm Curetis has successfully completed a large clinical trial of its lower respiratory panel (LRP) in anticipation of submitting the panel and its Unyvero system to the US Food and Drug Administration by the end of the year.

The panel is designed for critical lower respiratory tract infections, which are often diagnosed as pneumonia, and detects 21 different pathogens and 19 resistance markers, Curetis' CEO Oliver Schacht told GenomeWeb in an interview. It is currently CE-marked in Europe, where it is known as a pneumonia panel.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.